Intec Pharma Ltd. (NASDAQ:NTEC) has been assigned a $10.00 price objective by equities research analysts at Roth Capital in a research note issued to investors on Thursday. The brokerage presently has a “buy” rating on the biotechnology company’s stock. Roth Capital’s target price points to a potential upside of 88.68% from the company’s previous close.

A number of other equities research analysts also recently issued reports on the stock. Maxim Group set a $9.00 price target on shares of Intec Pharma and gave the stock a “buy” rating in a report on Wednesday, May 24th. Zacks Investment Research downgraded shares of Intec Pharma from a “buy” rating to a “hold” rating in a report on Wednesday, May 24th. Finally, ValuEngine downgraded shares of Intec Pharma from a “hold” rating to a “sell” rating in a report on Friday, June 9th.

Intec Pharma (NASDAQ:NTEC) traded down 3.77% during midday trading on Thursday, reaching $5.10. 12,296 shares of the company’s stock traded hands. The stock’s 50 day moving average price is $5.47 and its 200 day moving average price is $5.25. Intec Pharma has a 1-year low of $4.20 and a 1-year high of $6.36. The firm’s market cap is $70.06 million.

TRADEMARK VIOLATION WARNING: This piece of content was first published by Daily Political and is owned by of Daily Political. If you are viewing this piece of content on another site, it was stolen and reposted in violation of US and international copyright law. The original version of this piece of content can be viewed at

Intec Pharma Company Profile

Intec Pharma Ltd is an Israel-based drug development company. It is a development stage biopharmaceutical company that develops formulations of drugs using its proprietary gastric retention technology, the Accordion Pill. The Accordion Pill, a novel gastro-retentive delivery system, improves the pharmacokinetics and pharmacodynamics of various drugs.

Receive News & Ratings for Intec Pharma Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intec Pharma Ltd. and related companies with's FREE daily email newsletter.